• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Methyltransferase Assay Kits
      • Ligase and Synthetase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • AMPK Assay Kits
      • cGAS Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • TBK1 Assay Kits
    • Recombinant cGAS Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • OAS1 Assay Services
  • Innate Immunity
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD39 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Battling Autoimmune Disorders Using JAK1 Inhibitors

by Bellbrook Labs / Wednesday, 12 August 2020 / Published in HTS Assays, News
JAK1 Inhibitors for Autoimmune Disease

Could specific JAK1 inhibitors lead to better treatments for autoimmune disease? – The human immune response is complex with numerous cellular pathways playing a role. And, when an abnormal immune response results from one’s own body, known as an autoimmune disorder – it adds to the complexity. While we often think of celiac disease, inflammatory bowel disease, multiple sclerosis, psoriasis, lupus, or rheumatoid arthritis (RA) as common autoimmune disorders, there are over a hundred others. 2

Since cytokines (a variety of proteins involved in cell signaling) have a responsibility in driving and regulating the immune response, an imbalance can contribute to autoimmune disease. Janus kinases (JAK) including JAK1 are tyrosine kinases that activate cytokines by offering a phosphate group, taking from ATP leaving ADP as a result of phosphorylation.3

JAK1 is just one of several cytokine signaling enzymes that continue to be evaluated in order to mitigate unhealthy immune response such is the case with autoimmune disorders.

JAK-STAT Signaling Pathway

Signal transducer and activator of transcription (STAT) proteins are a family of transcription factors that through a chain of reactions ultimately lead to cellular immunity, proliferation, apoptosis, and differentiation. 3 Once a cytokine (be it interferons, interleukins, or a different type) binds to its receptor, JAK proteins are activated. JAKs in turn phosphorylate the cytokine receptor allowing for subsequent STAT binding which is then able to relocate to the nucleus where transcription occurs. In normal cells, this pathway enhances the immune response to fight unwanted disease. Genome studies have found a multitude of polymorphisms in many of the proteins involved in this pathway which contribute to autoimmune and inflammatory disorders.1,3

JAK1 Inhibitors

While the development and success of JAK inhibitors has been around for a while; Imatinib has been treating hematologic disorders since early 2000s, it’s only recently that these inhibitors are being developed for autoimmune disorders such as RA and psoriasis.1  Researchers at Sareum are excited about a recent small molecule discovery that through inhibition of TYK2/JAK1, patients suffering from an excess of interleukin 22 (IL-22) causing psoriasis could get some relief.4  Additionally, a newly FDA approved JAK1/JAK2 inhibitor (Tofacitinib) which blocks several cytokines including IL-2, IL-4, IL-15, and IL-21 shows promise in treating RA patients.1

It’s important to keep in mind how the immune system works with interconnectivity and dependency between molecules and pathways.  What works for one autoimmune disorder might not be the answer to another. Finding the precise JAK inhibitor for the targeted disorder is one path with great potential to treat some autoimmune conditions.

References

  1. Furumoto, Y., & Gadina, M. (2013). The arrival of JAK inhibitors: Advancing the treatment of immune and hematologic disorders. BioDrugs, 27(5), 431–438. https://doi.org/10.1007/s40259-013-0040-7
  2. Keren, D. F. (2013). Autoimmune Disease. The Immunoassay Handbook, 869–890. https://doi.org/10.1016/B978-0-08-097037-0.00069-5
  3. O’Shea, J. J., Kontzias, A., Yamaoka, K., Tanaka, Y., & Laurence, A. (2013). Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases, 72(SUPPL. 2). https://doi.org/10.1136/annrheumdis-2012-202576
  4. Works, M. G., Yin, F., Yin, C. C., Yiu, Y., Shew, K., Tran, T.-T., … D’Andrea, A. (2014). Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis. The Journal of Immunology, 193(7), 3278–3287. https://doi.org/10.4049/jimmunol.1400205
Tagged under: Autoimmune Disease, Innate Immunity, JAK1 Inhibitors, Transcreener ADP Kinase Assay

What you can read next

Join us in San Francisco! ICBS 2014
Pink Stethascope DOT1L Breast Cancer Target 420 X 280
How a Methyltransferase Activity Assay Could Help Identify Novel Breast Cancer Treatments
Webinar Graphic
Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Researcher Using An ADP Assay

    Accelerating Discovery of Kinase Inhibitors Using an ADP Assay

    An ADP assay can be used to study the activity ...
  • Inhibitors of ENPP1 SLAS Discovery

    New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

    BellBrook scientist Meera Kumar and Robert Lowe...
  • GMP Assay for PDE Inhibitor Discovery

    Using a Universal GMP Assay for PDE Research

    A universal GMP assay to aid in PDE research an...
  • SLAS 2021

    Join Us for SLAS 2021 Virtual Conference

    BellBrook Labs will be exhibiting at SLAS 2021,...
  • New cGAS TR-FRET Assay

    New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

    Launched in November 2019, the Transcreener cGA...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2019 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP